Mel Antonen caught up with Rafael Palmeiro today after the Hall of Fame vote was announced. Palmeiro is understandable disappointed with his vote total. After saying some nice things about Roberto Alomar and saying that he thought he himself would get more support than he did, Palmeiro made an appeal to the voters:
“I hear some voters talk about how they’ll probably vote for Barry Bonds because he was a Hall of Famer before he (allegedly) took steroids. Well, why can’t they do the same thing for me? I had one bad mistake at the end of my career. Voters are putting too much weight on the one incident. I wish they would look at my whole career. If they want, why don’t they use throw out the last season of my career? I would still have Hall of Fame numbers.”
I’m actually kinda skeptical that Bonds will get in the Hall any time soon after he first becomes eligible. The voters drew a line in the sand today: if you’re merely suspected of ‘roiding, less than half of them will vote for you. If you were ever caught, you’re getting less than 20% of the vote. Bonds didn’t test positive, but there’s a mountain of evidence against him and I predict that he’ll be in Mark McGwireland when he comes up for a vote. Maybe 30%, because he was so darn good, but not much more.
As for Palmeiro: good luck thinking that people will change their minds on you, but they won’t.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.